| Surviving the US health care system
Cynthia Kline knew exactly what was happening to her when she suffered a heart attack at her home in Cambridge, Mass. She took the time to call an ambulance, popped some nitroglycerin tablets she had been prescribed in anticipation of just such an emergency, and waited for help to arrive. On paper, everything should have gone fine. Unlike tens of millions of Americans, she had health insurance coverage. The ambulance team arrived promptly. The hospital where she had been receiving treatment for her cardiac problems, a private teaching facility affiliated with the Harvard Medical School, was just a few minutes away. The problem was, the emergency room at the hospital, Mount Auburn, was full to overflowing. And it turned her away. The ambulance took her to another nearby hospital but the treatment she needed, an emergency catheterization, was not available there.
Anti-Cancer Activity Supports Further Development of Ispinesib in ...
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 06/28/07 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the final results from a multicenter Phase II clinical trial sponsored by GlaxoSmithKline (GSK), which evaluated ispinesib in patients with locally advanced or metastatic breast cancer. Ispinesib is a novel small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Ispinesib has arisen from a broad strategic collaboration between Cytokinetics and GlaxoSmithKline (GSK) to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. This Phase II clinical trial was designed to evaluate the safety and efficacy of ispinesib in the second- or third-line treatment of patients with locally advanced or metastatic breast cancer whose disease had recurred or progressed despite treatment with anthracyclines and taxanes.
Cytokinetics Announces Data From Phase II Clinical Trial of ...
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the final results from a multicenter Phase II clinical trial sponsored by GlaxoSmithKline (GSK), which evaluated ispinesib in patients with locally advanced or metastatic breast cancer. Ispinesib is a novel small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Ispinesib has arisen from a broad strategic collaboration between Cytokinetics and GlaxoSmithKline (GSK) to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. This Phase II clinical trial was designed to evaluate the safety and efficacy of ispinesib in the second- or third-line treatment of patients with locally advanced or metastatic breast cancer whose disease had recurred or progressed despite treatment with anthracyclines and taxanes.
|
